Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?
Journal of Xenobiotics – February 07, 2022
Source: OpenAlex
Summary
Psilocybin, a potent hallucinogen present in over 200 mushroom species, is showing profound promise in modern psychiatry. Synthesized in 1957, early clinical observations suggested its therapeutic potential for anxiety, mood disorders, and addiction. Despite its 1970 scheduling, renewed interest in chemical synthesis and alkaloids has propelled recent psychology and drug studies. Contemporary medicine now provides robust evidence for psilocybin's efficacy in treating conditions like pathological anxiety and addiction. This complementary and alternative medicine approach, often involving a psychotherapist, represents a significant advance.
Abstract
Psychedelics extracted from plants have been used in religious, spiritual, and mystic practices for millennia. In 1957, Dr. Hofmann identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although there were limitations related to the scientific design of many studies, clinical observations performed during the 1950s and 1960s showed a potential therapeutic effect of psilocybin for patients affected by depressive symptoms, anxiety, and conversion disorder. Psilocybin was classed as a schedule I substance in 1970, but the fascination with psychedelics has remained almost unchanged over time, promoting a new scientific interest starting in the 1990s. Recent studies have provided further evidence supporting the suggestive hypothesis of the therapeutic use of psilocybin for treating various psychiatric disorders, including pathological anxiety, mood depressive disorder, and addiction.